Gain Therapeutics
高管
查看带有其 14 名主要高管的组织结构图
Gain Therapeutics 搜索最多的简介
- Gene Mack, Chief Financial Officer and Interim Chief Executive Off...
- Hans Peter Hasler, Independent Member
- Jeffrey Riley, Independent Member
高管在Gain Therapeutics变化
- Gene Mack 曾任 Chief Financial Officer, 现任 Chief Financial Officer and Interim Chief Executive Officer (新闻发布的2024六月28号).
- Matthias Alder, Chief Executive Officer and Director, 已经离开公司 (新闻发布的2024六月28号).
- Gene Mack已作为Chief Financial Officer加入公司 (新闻发布的2024四月9号).
创建提醒
跟踪 Gain Therapeutics 的高管变动
生物技术
Gain Therapeutics 拥有 2,328 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Integral Diagnostics and Capitol Health Limited have announced they will merge (公布2024十一月26号)..
- Inbrain Neuroelectronics 刚刚宣布为 50 筹款数百万美元。 (公布2024十一月23号).
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
生物技术 行业的其他推荐联系人
消息
Gain Therapeutics 的最新新闻稿
- GT-02287 may slow Parkinson’s progression, new early data suggest
- 10 Maryland Life Science Companies Pioneering AI Innovation
- Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
- GT-02287 may slow Parkinson's progression: New preclinical data
- Understanding the Therapeutic Potential of GT-02287 in GBA-Parkinson Disease
- Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
- Gain Therapeutics - Home
- Gain Therapeutics
- Gain Therapeutics
- Gain Therapeutics - Home
- View more press releases Close
通过电子邮件
